

9. (Amended) A method according to claim 6, which comprises the administration of 8 to 12 mg of Compound (I).

10. (Amended) A method according to claim 7, which comprises the administration of 2 mg of Compound (I).

11. (Amended) A method according to claim 8, which comprises the administration of 4 mg of Compound (I).

12. (Amended) A method according to claim 8, which comprises the administration of 8 mg of Compound (I).

16. (Amended) A composition according to claim 14, wherein the insulin secretagogue is glibenclamide, glipitide, gliclazide, glimepiride, tolazamide or tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glycopyramide, glycylamide or repaglinide.

18. (Amended) A composition according to claim 14, wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione (Compound I).

19. (Amended) A composition according to claim 14, which comprises 2 to 12 mg of Compound (I).

20. (Amended) A pharmaceutical composition comprising an insulin sensitiser, an insulin secretagogue and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.

22. (Amended) A composition according to claim 14, wherein the insulin sensitiser is (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydro-benzopyran)-5-ylmethyl]thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable form thereof.